[{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zotatifin","moa":"||eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Prof. Wolfgang Janni","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase IV","graph3":"Prof. Wolfgang Janni","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prof. Wolfgang Janni \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Prof. Wolfgang Janni \/ Eli Lilly"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sermonix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sermonix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"West German Study Group","sponsor":"Eli Lilly | Genomic Health, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase III","graph3":"West German Study Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"West German Study Group \/ Eli Lilly | Genomic Health, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"West German Study Group \/ Eli Lilly | Genomic Health, Inc."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Sarcoma Alliance for Research through Collaboration","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase III","graph3":"Sarcoma Alliance for Research through Collaboration","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sarcoma Alliance for Research through Collaboration \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Sarcoma Alliance for Research through Collaboration \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Abemaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Agilent Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Agilent Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Agilent Technologies"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Care Access Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Abemaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase III","graph3":"Care Access Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Care Access Research \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Care Access Research \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Imlunestrant","moa":"||Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"University of Tennessee Health Science Center","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"University of Tennessee Health Science Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of Tennessee Health Science Center \/ US Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"University of Tennessee Health Science Center \/ US Department of Defense"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sermonix Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sermonix Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sermonix Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Sermonix Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Exactis Innovation","sponsor":"Sermonix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Partnership","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exactis Innovation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exactis Innovation \/ Sermonix Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Exactis Innovation \/ Sermonix Pharmaceuticals"},{"orgOrder":0,"company":"GOG Foundation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"GOG Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GOG Foundation \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"GOG Foundation \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Anita Turk","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Anita Turk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anita Turk \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Anita Turk \/ Eli Lilly"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MEDSIR \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"MEDSIR \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly | Genentech"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"Kom Op Tegen Kanker | Eli Lilly | European Network for Gynaecological Oncological Trial Groups","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ Kom Op Tegen Kanker | Eli Lilly | European Network for Gynaecological Oncological Trial Groups","highestDevelopmentStatusID":"8","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ Kom Op Tegen Kanker | Eli Lilly | European Network for Gynaecological Oncological Trial Groups"},{"orgOrder":0,"company":"Nader Sanai","sponsor":"Eli Lilly | Barrow Neurological Institute | Ivy Brain Tumor Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Nader Sanai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nader Sanai \/ Eli Lilly | Barrow Neurological Institute | Ivy Brain Tumor Center","highestDevelopmentStatusID":"8","companyTruncated":"Nader Sanai \/ Eli Lilly | Barrow Neurological Institute | Ivy Brain Tumor Center"},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"Kom Op Tegen Kanker | Eli Lilly | Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ Kom Op Tegen Kanker | Eli Lilly | Teva Pharmaceutical Industries","highestDevelopmentStatusID":"8","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ Kom Op Tegen Kanker | Eli Lilly | Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INX-315","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyclix Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Criterium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Criterium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Criterium \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Criterium \/ Inapplicable"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moffitt Cancer Center \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Eli Lilly"},{"orgOrder":0,"company":"Vadim S Koshkin","sponsor":"Prostate Cancer Foundation | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vadim S Koshkin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vadim S Koshkin \/ Prostate Cancer Foundation | Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Vadim S Koshkin \/ Prostate Cancer Foundation | Eli Lilly"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Eli Lilly | Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Eli Lilly | Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Eli Lilly | Exelixis"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Abemaciclib","moa":"||Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Abemaciclib","moa":"||CHK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"INX-315","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyclix Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Inapplicable"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Bayer AG"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imlunestrant","moa":"||Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"National Comprehensive Cancer Network","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ National Comprehensive Cancer Network","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ National Comprehensive Cancer Network"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"University of Alabama at Birmingham \/ Eli Lilly"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Irvine \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Irvine \/ Eli Lilly"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Eli Lilly"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"University of California, San Diego \/ Eli Lilly"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"Oregon Health and Science University | Eli Lilly | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ Oregon Health and Science University | Eli Lilly | AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"OHSU Knight Cancer Institute \/ Oregon Health and Science University | Eli Lilly | AstraZeneca"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"INX-315","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyclix Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Nader Sanai","sponsor":"Barrow Neurological Institute | Ivy Brain Tumor Center | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I","graph3":"Nader Sanai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nader Sanai \/ Barrow Neurological Institute | Ivy Brain Tumor Center | Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Nader Sanai \/ Barrow Neurological Institute | Ivy Brain Tumor Center | Eli Lilly"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"Eli Lilly | GSK | Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ Eli Lilly | GSK | Oregon Health and Science University","highestDevelopmentStatusID":"8","companyTruncated":"OHSU Knight Cancer Institute \/ Eli Lilly | GSK | Oregon Health and Science University"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Eli Lilly"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Eli Lilly"}]

Find Clinical Drug Pipeline Developments & Deals for Abemaciclib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : INX-315, a novel, potent and selective CDK2 inhibitor, which is being evaluated for the treatment of CCNE1-Amplified Platinum-Resistant/Refractory Ovarian Cancer.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 29, 2025

                          Lead Product(s) : INX-315,Fulvestrant,Abemaciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 19, 2025

                          Lead Product(s) : Abemaciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Eli Lilly | Exelixis

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : INX-315 is a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio (abemaciclib) and fulvestrant for the treatment of HR+/HER2- Breast Cancer.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 13, 2024

                          Lead Product(s) : INX-315,Abemaciclib,Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : LY3484356 (imlunestrant) is a brain-penetrant, oral selective estrogen receptor degrader (SERD), which is being evaluated for the treatment of ER+, HER2- Advanced Breast Cancer.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 11, 2024

                          Lead Product(s) : Imlunestrant,Abemaciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : ARV-471 (vepdegestrant) is an investigational PROTAC protein degrader designed to target and degrade the estrogen receptor. It is being evaluated for the treatment of ER+/HER2- breast cancer.

                          Product Name : Undisclosed

                          Product Type : PROTACs

                          Upfront Cash : Inapplicable

                          December 10, 2024

                          Lead Product(s) : Vepdegestrant,Abemaciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The collaboration aims to evaluate INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio (abemaciclib) and fulvestrant in HR+/HER2- Breast Cancer.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 18, 2024

                          Lead Product(s) : INX-315,Abemaciclib,Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Eli Lilly

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 07, 2024

                          Lead Product(s) : Abemaciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Eli Lilly

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OHSU Knight Cancer Institute

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          OHSU Knight Cancer Institute

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Lead Product(s) : Abemaciclib

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : Oregon Health and Science University | Eli Lilly | AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 08, 2024

                          Lead Product(s) : Abemaciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Oregon Health and Science University | Eli Lilly | AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : HLX78 (lasofoxifene) receives approval to join the ongoing global registrational ELAINE-3 trial with responsibility in China for the treatment of ER+/HER2 ESR1-mutated Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : HPAPI

                          Upfront Cash : Inapplicable

                          August 06, 2024

                          Lead Product(s) : Lasofoxifene,Abemaciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 14, 2024

                          Lead Product(s) : Abemaciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank